Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

ectibix plus FOLFOX significantly  improved PFS versus FOLFOX alone (median 9.6 months versus 8.0 months, hazard ratio (HR) 0.80; 95 percent confidence interval (CI): 0.66-0.97; p=0.02).(i)  Additionally, combining Vectibix with FOLFOX resulted in numerically greater OS versus FOLFOX alone (median 23.9 months versus 19.7 months, HR 0.83; 95 percent CI: 0.67-1.02), although this was not statistically significant (p=0.072).(i)  The ORR achieved with Vectibix plus FOLFOX was higher than FOLFOX alone (55 percent versus 48 percent).(i)

The '181 study showed that adding Vectibix (6.0 mg/kg every two weeks) to FOLFIRI chemotherapy improved median PFS by two months in patients with wild-type KRAS mCRC compared to FOLFIRI alone (median 5.9 months versus 3.9 months; HR 0.73, 95 percent CI: 0.59-0.90; p=0.004). Additionally, the Vectibix combination more than tripled the ORR compared to FOLFIRI alone (35 percent versus 10 percent). Though quantitatively greater (14.5 months versus 12.5 months, HR 0.85), the improvement in median OS (co-primary endpoint) did not achieve statistical significance in the Vectibix arm of the trial (p=0.12).(ii)

Adverse event rates included known toxicities associated with anti-epidermal growth factor receptor (EGFR) therapy, such as rash, diarrhea, and hypomagnesemia. Vectibix-related grade 3/4 infusion reactions were reported in less than one percent of patients. (i)  In patients with mutated KRAS tumors, outcomes were inferior for those receiving Vectibix plus FOLFOX versus FOLFOX alone.(ii iii) Vectibix should only be used in those patients in whom wild-type KRAS status has been confirmed, because of the worse outcomes in patients with mutated KRAS tumors treated with FOLFOX.

The Amgen PRIME and '181 studies were the first Phase 3 studies to prospectively analyze the effect of an EGFR inhibitor based on KRAS status in patients with mCRC.

Vectibix is already approv
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
(Date:5/23/2013)... EASTON, Mass. , May 23, 2013 ... today announced that the Company will host a teleconference ... to provide a business update. The teleconference information is ... Time: 11:00 a.m. Eastern Daylight Time (EDT) ... ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
(Date:5/23/2013)... 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE (Europe) approved Total Artificial ... Scotland, which boasts more than 380,000 visitors annually, is ... powered by the Freedom® portable driver as part of ... advanced exhibitions of its kind. , “BodyWorks combines ...
(Date:5/23/2013)... May 23, 2013 Watlow®, an ... complete thermal systems, recently introduced its new catalog, ... of experience in designing and manufacturing industrial heaters, ... products to serve diverse customer needs. , A ... at the beginning of the book. These options ...
Breaking Biology Technology:Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Watlow Introduces Its New Industrial Heater Catalog 2
... 15 BioMed Realty Trust, Inc.,(NYSE: BMR ) today ... 2008 dividend of $0.335 per share of common stock. The,dividend ... share., BioMed also announced that its board of directors ... 7.375% Series A Cumulative,Redeemable Preferred Stock for the period from ...
... division of Nycomed,US Inc., today announced the FDA ... formulation compares to Taro,s Referenced Listed Drug (RLD),and ... # 0168-0133-15), 30g tubes,(NDC # 0168-0133-30) and 45g ... Clotrimazole Cream is another illustration of,Fougera,s robust product ...
... HAYWARD, Calif., Sept. 12 Acologix, Inc., a ... two,preclinical studies demonstrating that AC-100, its therapeutic product,candidate ... bone and,dental cells, promotes cartilage regeneration in large ... Catherine A. Middleton-Hardie on September,13, 2008 at the ...
Cached Biology Technology:BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends 2Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 2Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 3
(Date:5/23/2013)... (May 23, 2013) A new report from ... for helping pupils engage in at least 60 minutes ... day. , No more than half of American youth ... of vigorous or moderate intensity physical activity daily, according ... "Because children are in school for nearly half of ...
(Date:5/23/2013)... Publishing in Neuron , the team reveal the ... in work funded by the Wellcome Trust and BBSRC. ... external stimuli we improve our perceptual abilities. While these ... they can also affect the fidelity of that response. ... Visual Neuroscience explains: "When you communicate with others, you ...
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Tests lead to doubling of fuel cell life 2
... biochemistry is how proteins recognize "correct" interaction partners in ... critical to know than in the brain, where interactions ... A team of biologists at the Salk Institute for ... regulates availability of a brain channel that modulates neuronal ...
... March 22, 2011 BGI (previously known as the ... world, announced its participation and pivotal role in the ... systematically determine the functional and evolutionary diversity of microbial ... planet and mankind. Unlike past microbial studies ...
... are transfused in the US every year. Routine blood screening ... C, HIV types 1 and 2, and syphilis, but not ... to chronic fatigue syndrome. A symposium at the New York ... in the testing and screening of the blood supply, diagnose ...
Cached Biology News:Salk scientists crack molecular code regulating neuronal excitability 2Salk scientists crack molecular code regulating neuronal excitability 3BGI to Play Pivotal Sampling, Next-Generation Sequencing and Bioinformatics Role in Earth Microbiome Project 2BGI to Play Pivotal Sampling, Next-Generation Sequencing and Bioinformatics Role in Earth Microbiome Project 3BGI to Play Pivotal Sampling, Next-Generation Sequencing and Bioinformatics Role in Earth Microbiome Project 4
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
MDMA Mouse Monoclonal Antibody (Clone 3G8)...
... Immunogen: ... region encompassing the human, mouse, ... Accession Number: ... Assurance: Routinely evaluated by ...
TTC4 Antibody...
Biology Products: